The company intends to use the funds to support its clinical development, regulatory submission, and planned commercial launch of its lead investigational therapy, dibotatug (DR-01), expand it into additional indications, and accelerate the development of its broader pipeline across oncology, immunology, and neurology.

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

733 Industrial Rd.
San Carlos, CA 94070
USA

Phone

Undisclosed

Website

www.drenbio.com

Email Address

[email protected]

Overview

Dren Bio is a biotechnology company developing powerful protein engineering technologies to deplete cells, protein aggregates and other disease-causing agents. Dren's lead programs are initially focused on hematologic neoplasms and solid cancers. Dren is actively working in other areas including auto-immune disorders and diseases of protein aggregation.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Nenad Tomasevic

Chief Financial Officer

John Wesley

Browse more venture capital transactions:

Prev: 10/30/2026: Birch Hill Holdings venture capital transaction
Next: 10/30/2026: NoorNation venture capital transaction

Share this article

Where The Data Comes From

We do our best to report on every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary